{{cart_num}}
My Cart> Small Molecule Compounds > Inhibitors & Antagonists & Agonists > MAPK > AZ-628CAS：878739-06-1
Molecular Formula：C27H25N5O2
Molecular Weight：451.52
Storage：Powder:2-8℃，2 years;Insolvent(Mother Liquid):-20℃，6 months;-80℃，1 year
Purity：≥98%
Appearance：Solid
Qty：
Size：
| CAS | 878739-06-1 |
| Name | AZ-628 |
| Molecular Formula | C27H25N5O2 |
| Molecular Weight | 451.52 |
| Solubility | Soluble in DMSO ≥5mg/mL;Soluble in Water ＜ 0.1mg/mL |
| Purity | ≥98% |
| Appearance | Solid |
| Storage | Powder:2-8℃，2 years;Insolvent(Mother Liquid):-20℃，6 months;-80℃，1 year |
| MDL | MFCD17392577 |
| SMILES | O=C1N(C)C=NC2=C1C=C(C=C2)NC3=C(C)C=CC(NC(C4=CC(C(C#N)(C)C)=CC=C4)=O)=C3 |
| Target Point | Raf |
| Passage | MAPK |
| Background | AZ628 is a pan-Raf kinase inhibitor. |
| Biological Activity | AZ628 是一种泛 Raf 激酶抑制剂，抑制 B-Raf，B-RafV600E，和 c-Raf-1，IC50 分别为 105，34，和 29 nM。[1-2] |
| IC50 | c-Raf-1:29nM;B-RafV600E:34nM;B-Raf:105nM [1-2] |
| Data Literature Source | [1]. Khazak V，et al. Selective Raf inhibition in cancer therapy. Expert Opin Ther Targets. 2007 Dec;11(12):1587-609. [2]. Lau KS，et al. BAY61-3606 affects the viability of colon cancer cells in a genotype-directed manner. PLoS One. 2012;7(7):e41343 |
| Unit | Bottle |
| Specification | 5mg 10mg |
Remark：These protocols are for reference only. Solarbio does not independently validate these methods.
Note：
1. The products are all for scientific research use only. Do not use it for medical, clinical diagnosis or treatment, food and cosmetics, etc. Do not store them in ordinary residential areas.
2. For your safety and health, please wear laboratory clothes, disposable gloves and masks.
3. The experimental results may be affected by many factors, after-sale service is limited to the product itself and does not involve other compensation.
Sorry, there is no more information.
Sorry, there is no more information.
Sorry, there is no more information.
Manual Download
